Characterization of a Novel Mouse Model of Multiple Myeloma and Its Use in Preclinical Therapeutic Assessment

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Fryer, Rosemary A ^a   Graham, Timothy J ^a   Smith, Emma M ^a   Walker Samuel, Simon ^b   Morgan, Gareth J ^a   Robinson, Simon P ^a   Davies, Faith E ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPEPTIDASE INHIBITOR; ANTINEOPLASTIC AGENT; BORTEZOMIB; HISTONE DEACETYLASE INHIBITOR; MELPHALAN; PARAPROTEIN; SYNDECAN 1; TOSEDOSTAT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; CANCER CELL CULTURE; CELL COUNT; CELL INTERACTION; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR MICROENVIRONMENT; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE MARROW; BORONIC ACIDS; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENES, REPORTER; GRAFT SURVIVAL; HUMANS; INJECTIONS; LUCIFERASES; LUMINESCENT MEASUREMENTS; MAGNETIC RESONANCE IMAGING; MELPHALAN; MICE; MICE, INBRED NOD; MICE, SCID; MULTIPLE MYELOMA; NEOPLASM TRANSPLANTATION; PARAPROTEINS; PLASMA CELLS; PYRAZINES; SYNDECAN-1; TIBIA; TUMOR MICROENVIRONMENT;

EID: 84874336478     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057641     Document Type: Article

References (21)

1. Podar K, Richardson PG, Hideshima T, Chauhan D, Anderson KC, (2007) The malignant clone and the bone-marrow environment. Best Pract Res Clin Haematol 20: 597-612.
2. Radl J, De Glopper ED, Shuit HR, Zurcher C, (1979) Idiopathic paraproteinemia. II. Transplantation of the paraprotein producing clone from old to young C57BL/KaLwRij mice. J Immunol122: 609-613.
3. Gadó K, Silva S, Pálóczi K, Domján G, Falus A, (2001) Mouse plasmacytoma: an experimental model of human multiple myeloma. Haematologica86: 227-236.
4. Yata K, Yaccoby S, (2004) The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Leukemia 18: 1891-1897.
5. Boylan KLM, Gosse MA, Staggs SE, Janz S, Grindle S, et al. (2007) A transgenic mouse model of plasma cell malignancy shows phenotypic, cytogenetic, and gene expression heterogeneity similar to human multiple myeloma. Cancer Res 67: 4069-4078.
6. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, et al. (2011) BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146: 904-917.
7. Chesi M, Robbiani DF, Sebag M, Chng WJ, Affer M, et al. (2008) AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 13: 167-180.
8. Carrasco DR, Sukhdeo K, Protopopova M, Sinha R, Enos M, et al. (2007) The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell 11: 349-360.
9. Morito N, Yoh K, Maeda A, Nakano T, Fujita A, et al. (2011) A novel transgenic mouse model of the human multiple myeloma chromosomal translocation t(14;16)(q32;q23). Cancer Res 71: 339-348.
10. Groen RW, Hofhuis FM, Aalders L, van Kessel B, de Weers M, et al. (2010) A unique new humanized mouse model for multiple myeloma (MM): opportunities for studying MM in its natural environment and for preclinical testing. Blood (ASH Annual Meeting Abstracts)116: Abstract 981.
11. Calimeri T, Battista E, Conforti F, Neri P, Di Martino MT, et al. (2011) A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. Leukemia 25: 707-711.
12. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, et al. (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367: 645-648.
13. Löwenberg B, Morgan G, Ossenkoppele GJ, Burnett AK, Zachée P, et al. (2010) Phase I/II clinical study of tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia. J Clin Oncol 28: 4333-4338.
14. Moore HE, Davenport EL, Smith EM, Muralikrishnan S, Dunlop AS, et al. (2009) Aminopeptidase inhibition as a targeted treatment strategy in myeloma. Mol Cancer Ther 8: 762-770.
15. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, et al. (2010) Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102: 1555-1577.
16. Pattengale PK, (1997) Role of interleukin-6 in the pathogenesis of murine plasmacytoma and human multiple myeloma. Am J Pathol 151: 647-649.
17. Tong AW, Huang YW, Zhang BQ, Netto G, Vitetta ES, et al. (1993) Heterotransplantation of human multiple myeloma cell lines in severe combined immunodeficiency (SCID) mice. Anticancer Res 13: 593-597.
18. Miyakawa Y, Ohnishi Y, Tomisawa M, Monnai M, Kohmura K, et al. (2004) Establishment of a new model of human multiple myeloma using NOD/SCID/gammac(null) (NOG) mice. Biochem Biophys Res Commun 313: 258-262.
19. Mitsiades CS, Mitsiades NS, Bronson RT, Chauhan D, Munshi N, et al. (2003) Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. Cancer Res 63: 6689-6696.
20. Richmond A, Su Y, (2008) Mouse xenograft models vs GEM models for human cancer therapeutics. Dis Model Mech 1: 78-82.
21. Edinger M, Sweeney TJ, Tucker AA, Olomu AB, Negrin RS, et al. (1999) Noninvasive assessment of tumor cell proliferation in animal models. Neoplasia 1: 303-310.